ArticleFrontiers in immunology2014
Type I interferon in human autoimmunity.
Article in Frontiers in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus.Human molecular genetics · 2018Trial
- Single-nucleotide methylation specifically represses type I interferon in antiviral innate immunity.The Journal of experimental medicine · 2021Article
- Type I Interferon and the Spectrum of Susceptibility to Viral Infection and Autoimmune Disease: A Shared Genomic Signature.Frontiers in immunology · 2021Review
- Autoimmunity gene IRGM suppresses cGAS-STING and RIG-I-MAVS signaling to control interferon response.EMBO reports · 2020Article
- Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation inScience immunology · 2019Article
- Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement-A new target for lupus treatment.Science advances · 2019Article
- Cellular FLIP long isoform (cFLIPThe Journal of biological chemistry · 2018Article
- Type-I Interferons Inhibit Interleukin-10 Signaling and Favor Type 1 Diabetes Development in Nonobese Diabetic Mice.Frontiers in immunology · 2018Article
- A Type I Interferon and IL-10 Induced byFrontiers in immunology · 2018Article
- The Importance of Dendritic Cells in Maintaining Immune Tolerance.Journal of immunology (Baltimore, Md. : 1950) · 2017Review
- Interferon Lambda Genetics and Biology in Regulation of Viral Control.Frontiers in immunology · 2017Review
- Type I Interferon Is a Catastrophic Feature of the Diabetic Islet Microenvironment.Frontiers in endocrinology · 2017Review
- Beyond Immune Cell Migration: The Emerging Role of the Sphingosine-1-phosphate Receptor S1PR4 as a Modulator of Innate Immune Cell Activation.Mediators of inflammation · 2017Review
- T-cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases.Immunology and cell biology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.